Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer

Oncologist

Volumn 11, Issue 10, 2006, Pages 1072-1080

  Gholam, Dany ^a,b,c   Giacchetti, Sylvie ^a,b,c   Brézault Bonnet, Catherine ^a,b,c   Bouchahda, Mohamed ^a,b,c   Hauteville, Dominique ^b   Adam, René ^a   Ducot, Béatrice ^c,d   Ghémard, Odile ^b   Kustlinger, Francis ^b   Jasmin, Claude ^b,c   Lévi, Francis ^a,b,c  

^a INSERM   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Chronotherapy; Circadian rhythm; Irinotecan; Metastatic colorectal cancer; Oxaliplatin; Salvage treatment

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHRONOTHERAPY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33751213381     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-10-1072     Document Type: Article

References (43)

1. Lévi FA, Zidani R, Vannetzel JM et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-1617.
2. Lévi F, Zidani R, Misset JL. Randomized multicenter trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-686.
3. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicentre randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and 5-fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
6. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
7. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
8. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
10. O'Neil BH, Goldberg RM. Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can). Semin Oncol 2005;32:35-42.
11. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
12. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-657; discussion 657-658.
13. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
14. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
15. Mormont MC, Lévi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003;97:155-169.
16. Harris BE, Song R, Soong SJ et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
17. Lévi F, Metzger G, Massari C et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000;38:1-21.
18. Lincoln DW 2nd, Hrushesky WJ, Wood PA. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer 2000;88:479-485.
19. Ohdo S, Makinosumi T, Ishizaki T et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997;283:1383-1388.
20. Granda TG, D'Attino RM, Filipski E et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999-1005.
21. Filipski E, Lemaigre G, Liu XH et al. Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int 2004;21:613-630.
22. Giacchetti S, Curé H, Adenis A et al. Chronomodulated irinotecan (CPT) versus standard infusion in patients with metastatic colorectal cancer, a randomized multicenter trial. Eur J Cancer 2001;37:S309.
23. Smaaland R, Laerum OD, Lote K et al. DNA synthesis in human bone marrow is circadian stage dependant. Blood 1991;77:2603-2611.
24. Bjarnason GA, Jordan RC, Wood PA et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 2001;158:1793-1801.
25. Hagrman D, Goodisman J, Souid AK. Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 2004;308:658-666.
26. Smaaland R, Svardal AM, Lote K et al. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst 1991;83:1092-1098.
27. Zeng ZL, Sun J, Guo L et al. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol Int 2005;22:741-754.
28. Fischel JL, Rostagno P, Formento P et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 2001;84:579-585.
29. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002;20:165-172.
30. Falcone A, Masi G, Allegrini G et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:4006-4014.
31. Souglakos J, Mavroudis D, Kakolyris S et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002;20:2651-2657.
32. Lévi F, Zidani R, Brienza S et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5 fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-2540.
33. Mormont MC, Waterhouse J, Bleuzen P et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-3045.
34. Kohler U, Kreuter F. Data Analysis Using Stata. College Station. TX: Stata Press, 2005:1-395.
35. Garufi C, Bria E, Vanni B et al. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Br J Cancer 2003;89:1870-1875.
36. Lévi F, Zidani R, Coudert B et al. Chronomodulated irinotecan (I) - fluorouracil (F) - leucovorin (L) - oxaliplatin (O) (chrono IFLO) as salvage therapy in patients with heavily pretreated metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 2001;20:139a.
37. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
38. Rich T, Innominato PF, Boerner J et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:1757-1764.
39. Garufi C, Bjarnason A, Giacchetti S et al. Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients with metastatic colorectal cancer receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin. Proc Am Soc Clin Oncol 2005;24:259s.
40. Sephton SE, Sapolsky RM, Kraemer HC et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
41. Fu L, Pelicano H, Liu J et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
42. Filipski E, King VM, Li X et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002;94:690-697.
43. Filipski E, Innominato PF, Wu MW et al. Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl Cancer Inst 2005;97:507-517.